E28: Current state of public & private markets, Archegos debacle, US debt issues, wealth tax & more

Episode Summary

Executive Summary: The episode centers on frothy markets, SPAC retrading, private-market valuation inflation, leverage risk, and a broader political argument about debt, taxes, and the trade-off between freedom and equality. The hosts also discuss Archegos as a cautionary tale, debate wealth taxes and infrastructure spending, and revisit COVID vaccine efficacy and public-health messaging.

Main Topics: SPAC and PIPE market retrading (Priority: 5/5): The hosts describe a sharp tightening in SPAC/PIPE financing, with deals being repeatedly renegotiated and discounted as market conditions worsen and retail enthusiasm cools. Private-market valuation froth (Priority: 5/5): They compare current seed and growth valuations to prior years, arguing that startup prices are unusually high and forcing investors to consider backing existing winners instead of chasing new deals. Leverage, Archegos, and systemic risk (Priority: 5/5): A long discussion explains how Archegos used opaque derivatives and leverage to build hidden positions, why counterparties allowed it, and how forced unwinds can cascade through banks and markets. U.S. debt, deficits, and spending (Priority: 4/5): The group debates the size and sustainability of U.S. debt, COVID-era stimulus, infrastructure bills, and whether low rates are masking a future fiscal problem. Wealth tax and redistribution (Priority: 4/5): They argue over California's proposed wealth tax, the feasibility of taxing billionaires, and whether such policies would drive capital and talent out of the state. Freedom vs. equality (Priority: 4/5): A philosophical exchange frames markets, innovation, and prosperity as products of freedom, while warning that political pressure for equality can reduce growth and incentives. COVID vaccines, masks, and expert authority (Priority: 3/5): The hosts revisit vaccine efficacy, transmission reduction, and criticize public-health authorities for giving overly cautious guidance that later appeared unsupported by evidence.

Key Arguments: SPAC capital has been raised at historic levels, but the back end is now weakening: deals are being retraded, side terms are changing, and many PIPEs are failing to clear. Private valuations are extremely elevated, especially in seed and SaaS, so investors should allocate more capital to existing portfolio companies rather than overpay for new entries. Archegos showed how opaque leverage and derivatives can create enormous notional exposure and force banks into losses when a concentrated trade turns against the holder. Leverage is attractive because small returns can become huge on equity, but it magnifies ruin risk and can trigger systemic knock-on effects when multiple counterparties unwind at once. U.S. government debt is becoming dangerous because low interest rates hide the burden; if rates rise, debt service could crowd out spending on defense, entitlements, and other priorities. California's wealth tax is likely to be counterproductive because wealthy residents can move, taking taxes, investment, jobs, and business formation with them. Freedom and innovation are linked: societies that maximize liberty tend to create more prosperity and breakthrough companies, even though inequality rises as a side effect. Public-health officials should have used more evidence-based, less paternalistic guidance; the hosts argue that vaccinated people were likely less likely to transmit COVID and that earlier advice was overly conservative.

Data Points: SPACs raised in Q1: 245-250 - Used to illustrate the extraordinary pace of SPAC fundraising in the first quarter. SPAC capital raised in Q1: about $10 billion - Approximate capital raised amid the SPAC boom. PIPEs in the market last week: about 50 - One speaker cited a bank source estimating only about 5 of 50 PIPEs would get done. PIPE completion rate previously: 80%-100% - They contrasted current PIPE difficulty with an earlier period when most deals were getting done. Seed valuation range previously: $5M-$10M - Pre-revenue seed rounds used to price much lower than today. Hot seed valuations now: $27M-$30M - Current hot pre-revenue seed deals are described as having much higher caps. Typical seed round size: $3M-$6M - The round size associated with those high seed valuations. Valuation increase: about 2x year-over-year - Private market prices across seed, A, B, and growth are described as roughly doubling. Archegos criminal/civil penalty: $60 million - Bill Hwang reportedly paid this after his insider-trading case. Archegos notional exposure: about $50 billion - The discussion estimates leverage turned a $5B-$10B book into roughly $50B of exposure. Prime broker loss estimate: $2 billion - Nomura warned of significant losses from unwinding Archegos-related trades. U.S. debt-to-GDP: 130% - Used to argue the United States is over-levered as a country. Federal deficit: $4.5 trillion - Referenced as the government’s current annual deficit level during the discussion. COVID stimulus already passed: $1.9 trillion - Biden's earlier pandemic relief bill. Infrastructure bill: about $2 trillion - Described as the major infrastructure package under debate. Additional families/social bill: $1-2 trillion - A second package discussed as potentially following the infrastructure bill. Corporate tax proposal: 21% to 28% - Planned increase in the corporate tax rate. Top individual rate proposal: 39.6% above $400,000 - Referenced as part of the proposed tax changes. California wealth tax proposal: 1% over $50M; 1.5% over $1B - The state proposal discussed in detail. Estimated California wealth tax revenue: over $22 billion - A static estimate that the hosts argue would be overstated due to migration. California billionaires: 169 - The number cited as potentially affected by the wealth tax. Vaccination throughput: over 3 million/day - California vaccination pace mentioned in relation to reopening and live events. First-shot efficacy: about 80% - They cite a paper suggesting substantial protection after one dose. Second-shot efficacy: about 90% - Protection after the second dose is described as higher but not dramatically so.

Pivotal Quotes: "If I had to pay 1.5% a year, I'm like, okay, what is the marginal utility of that money for me? It's basically zero." — Chamath: On the proposed California wealth tax and why the financial burden itself is less objectionable than perceived waste. "Democracy is not two wolves and a sheep voting on what they're going to have for dinner." — Sachs: Explaining why rights and constitutional protections are needed to limit majoritarian taxation and confiscation. "Freedom produces prosperity." — Friedberg: Summarizing the argument that markets and liberty generate growth, though with some inequality.

Implications: The episode suggests tighter capital discipline ahead: SPACs, venture, and leveraged trades may face harsher terms, while states and governments pursuing aggressive redistribution could trigger capital flight and slower growth. It also reflects a shift toward evidence-based, less deferential thinking in health and policy.